Are Sino-Platinum Metals Co.,Ltd's (SHSE:600459) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Sino-Platinum MetalsLtd (SHSE:600459) has had a rough three months with its share price down 7.7%. However, stock prices are usually driven by a company's financials over the long term, which in

Simply Wall StJul 15 02:49 ET

Sino-Platinum Metals (600459.SH) will distribute a dividend of 0.19006 yuan per share for the year 2023, with a record date of July 3.

Sino-Platinum Metals (600459.SH) has announced that the company will distribute equity dividends for the year 2023, with a payout of per share...

Zhitong FinanceJun 26 07:15 ET

The Three-year Underlying Earnings Growth at Sino-Platinum MetalsLtd (SHSE:600459) Is Promising, but the Shareholders Are Still in the Red Over That Time

As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report

Simply Wall StJun 26 00:12 ET

Sino-Platinum Metals Co.,Ltd (SHSE:600459) Might Not Be As Mispriced As It Looks

Sino-Platinum Metals Co.,Ltd's (SHSE:600459) price-to-earnings (or "P/E") ratio of 22x might make it look like a buy right now compared to the market in China, where around half of the companies have

Simply Wall StJun 7 18:53 ET

Sino-Platinum Metals (600459.SH) subsidiary plans to invest 100 million yuan to establish Guixian Chemical Pharmaceuticals Co., Ltd.

On June 3rd, Gelonhui reported that Sino-Platinum Metals (600459.SH) announced that its wholly-owned subsidiary, Guiyan Chemical Materials (Yunnan) Co., Ltd. (referred to as "Guiyan Chemical"), invested RMB 100 million to establish a wholly-owned subsidiary, Guiyan Chemical Pharmaceuticals Technology (Yunnan) Co., Ltd. (referred to as "Guiyan Chemical Pharmaceuticals Company" or "New Company") (subject to the final registration of the Administration for Industry and Commerce). With the construction of the "platinum anticancer drug active pharmaceutical ingredient industrialization project" as the basis, the company will extend downstream processing of precious metal anticancer drug active pharmaceutical ingredient precursor products, make up for the short board of the company's precious metal active pharmaceutical ingredient industry, and strive to become a leading enterprise in the field of chemical pharmaceuticals and technology.

Gelonghui FinanceJun 3 06:32 ET

Sino-Platinum MetalsLtd (SHSE:600459) Could Be Struggling To Allocate Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. In a perfect world, we'd like to see a company investing more cap

Simply Wall StMay 20 23:39 ET